Stockscreener 앱 받기
4.24
5.99%
-0.27
시간 외 거래:
4.24
전일 마감가:
$4.51
열려 있는:
$4.44
하루 거래량:
156.67K
Relative Volume:
0.68
시가총액:
$152.89M
수익:
-
순이익/손실:
-
주가수익비율:
-2.1431
EPS:
-1.9784
순현금흐름:
-
1주 성능:
+16.48%
1개월 성능:
-23.05%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$4.09
$4.4999
1주일 범위
$3.72
$5.175
52주 변동 폭
$2.34
$8.79
Anteris Technologies Global Corp Stock (AVR) Company Profile
명칭
Anteris Technologies Global Corp
전화
651-493-0606
주소
860 BLUE GENTIAN ROAD, EAGAN
AVR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVR
Anteris Technologies Global Corp
|
4.24 | 130.82M | 0 | 0 | 0 | -1.9784 |
|
ISRG
Intuitive Surgical Inc
|
552.34 | 193.38B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
172.59 | 49.12B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
85.94 | 42.79B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
244.79 | 35.61B | 5.02B | 1.31B | 1.56B | 8.91 |
|
BAX
Baxter International Inc
|
30.50 | 15.46B | 11.89B | -560.00M | 191.00M | -1.10 |
Anteris Technologies Global Corp Stock (AVR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-08 | 개시 | Lake Street | Buy |
| 2025-01-07 | 개시 | Barclays | Overweight |
| 2025-01-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-01-07 | 개시 | TD Cowen | Buy |
Anteris Technologies Global Corp 주식(AVR)의 최신 뉴스
Will Anteris' DurAVR Spark A Paradigm Shift In The Transcatheter Aortic Valve Replacement Landscape? - RTTNews
Citadel Advisors LLC Makes New Investment in Anteris Technologies Global Corp (NASDAQ:AVR) - Defense World
Critical Survey: Anteris Technologies Global (NASDAQ:AVR) and Vicarious Surgical (NYSE:RBOT) - Defense World
Anteris Technologies advances toward PARADIGM trial after key regulatory and clinical milestones - Proactive financial news
Anteris Technologies Issues New Employee Incentive Securities - TipRanks
Anteris scales for pivotal PARADIGM Trial, plunging R&D investment into clinical activities - Proactive financial news
The morning catch up: ASX to extend gains as global optimism lifts markets - Proactive financial news
Anteris Technologies Advances Clinical Trial Efforts with DurAVR® THV - TipRanks
Anteris Technologies Reports Q1 2025 Results and Strategic Fund Allocation - TipRanks
Anteris Announces Results for the First Quarter of 2025 - The Manila Times
Company earnings calendar - Yahoo
Anteris Technologies Files Amendment to Annual Report - TipRanks
Anteris Technologies Announces Cessation of Certain Securities - TipRanks
Anteris Technologies Global Corp. (AVR) Receives a Buy from Lake Street - The Globe and Mail
ASX Runners of the Week: Redstone Resources, Anteris & Jindalee Lithium - businessnews.com.au
Cantor Fitzgerald maintains Anteris stock Overweight with $9 target By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains Anteris stock Overweight with $9 target - Investing.com
Anteris Technologies Announces Cessation of Securities - TipRanks
Anteris Technologies Announces New Securities Quotation - TipRanks
NanoVibronix (NASDAQ:NAOV) & Anteris Technologies Global (NASDAQ:AVR) Head to Head Review - Defense World
Anteris Technologies Reports March 2025 CDI Adjustments - TipRanks
Anteris Technologies Marks Clinical Milestone with DurAVR® THV By Investing.com - Investing.com Canada
Anteris reports over 100 patients treated with new heart valve By Investing.com - Investing.com South Africa
Anteris Technologies Hits Milestone with DurAVR® Heart Valve Treatment - Zenopa
Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV - GlobeNewswire
Anteris reports over 100 patients treated with new heart valve - Investing.com
Anteris Technologies announces 100 patients treated with DurAVR THV - TipRanks
Anteris Technologies Achieves Key Milestone in Cardiac Care - TipRanks
Anteris Technologies Marks Clinical Milestone with DurAVR® THV - Investing.com
Anteris Technologies marks clinical milestone with more than 100 patients treated using flagship DurAVR® THV - Proactive financial news
Anteris Technologies Achieves Milestone with DurAVR® Heart Valve - TipRanks
ASX Health Stocks: Anteris plans for US IPO and listing on Nasdaq - MSN
Head to Head Survey: Anteris Technologies Global (NASDAQ:AVR) & United Health Products (OTCMKTS:UEEC) - Defense World
Anteris Technologies reports one-year patient outcomes for DurAVR THV - TipRanks
Anteris shares rise on positive valve trial results By Investing.com - Investing.com Canada
Anteris Reports One-Year Patient Outcomes for DurAVR® THV - The Manila Times
Anteris shares rise on positive valve trial results - Investing.com India
Anteris Technologies Unveils Positive DurAVR® Patient Outcomes - TipRanks
Anteris Technologies delivers strong one-year results for DurAVR® Transcatheter Heart Valve - Proactive financial news
Analyzing Anteris Technologies Global (NASDAQ:AVR) & CollPlant Biotechnologies (NASDAQ:CLGN) - Defense World
Anteris Technologies Global Corp (AVR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Anteris Technologies Global Corp 주식 (AVR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Paterson Wayne | Chief Executive Officer |
Mar 05 '25 |
Option Exercise |
7.13 |
233,000 |
1,661,290 |
233,000 |
| Denaro Stephen | Director |
Mar 11 '25 |
Option Exercise |
7.13 |
16,500 |
117,645 |
23,722 |
0.66%
1.15%
자본화:
|
볼륨(24시간):